MISSION appoints new CEO
This article was originally published in Scrip
Cambridge, UK-based MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating enzyme family for the treatment of cancer and other diseases, has named Dr Anker Lundemose CEO. Dr Lundemose was most recently CEO of Norwegian vaccine company Bionor Pharma.
You may also be interested in...
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.